Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Schildkraut, JM, Bastos, E, Halabi, S, and Berchuck, A. "Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer - Response." JOURNAL OF THE NATIONAL CANCER INSTITUTE 89, no. 22 (November 19, 1997): 1727-1727.

Full Text

Choi, C, Cho, S, Horikawa, I, Berchuck, A, Wang, N, Cedrone, E, Jhung, SW, Lee, JB, Kerr, J, Chenevix-Trench, G, Kim, S, Barrett, JC, and Koi, M. "Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas." Genes, Chromosomes & Cancer 20, no. 3 (November 1997): 234-242.

Full Text

Berchuck, A, and Schildkraut, J. "Oral contraceptive pills. Prevention of ovarian cancer and other benefits." N C Med J 58, no. 6 (November 1997): 404-407. (Review)

Scholars@Duke

Risinger, JI, Hayes, AK, Berchuck, A, and Barrett, JC. "PTEN/MMAC1 mutations in endometrial cancers." Cancer Res 57, no. 21 (November 1, 1997): 4736-4738.

Scholars@Duke

Berchuck, A, and Carney, M. "Human ovarian cancer of the surface epithelium." Biochem Pharmacol 54, no. 5 (September 1, 1997): 541-544. (Review)

Scholars@Duke

Packenham, JP, du Manoir, S, Schrock, E, Risinger, JI, Dixon, D, Denz, DN, Evans, JA, Berchuck, A, Barrett, JC, Devereux, TR, and Ried, T. "Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization." Mol Carcinog 19, no. 4 (August 1997): 273-279.

Scholars@Duke

Schildkraut, JM, Bastos, E, and Berchuck, A. "Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer." J Natl Cancer Inst 89, no. 13 (July 2, 1997): 932-938.

Scholars@Duke

Lancaster, JM, Berchuck, A, Futreal, PA, and Wiseman, RW. "Dideoxy fingerprinting assay for BRCA1 mutation analysis." Molecular Carcinogenesis 19, no. 3 (July 1997): 176-179.

Full Text

Clifford, SL, Kaminetsky, CP, Cirisano, FD, Dodge, R, Soper, JT, Clarke-Pearson, DL, and Berchuck, A. "Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer." Am J Obstet Gynecol 176, no. 6 (June 1997): S229-S232.

Scholars@Duke

Mooney, EE, Robboy, SJ, Hammond, CB, Berchuck, A, and Bentley, RC. "Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis." Int J Gynecol Pathol 16, no. 2 (April 1997): 169-172.

Scholars@Duke

Pages